XML 158 R145.htm IDEA: XBRL DOCUMENT v3.23.1
Employees' Leaving Entitlement - Additional Information (Detail)
€ / shares in Units, $ in Thousands
 12 Months Ended
Jul. 15, 2022
EUR (€)
shares
Dec. 31, 2022
EUR (€)
shares
€ / shares
Dec. 31, 2021
EUR (€)
Jul. 15, 2022
USD ($)
Dec. 31, 2020
EUR (€)
Disclosure of classes of share capital [line items]          
Average duration of defined benefit plans   9 years 6 months 10 years 6 months    
Number of shares purchased   55,073,045      
Strike price relating tranche evaluation latter multiplied   5      
Number of ordinary shares   5      
Number of equity-based instruments granted 562,512        
Description of fair value measurement method of stock options granted   Expected volatility has been based on an evaluation of the historical volatility of both the price of the underlying ADSs of Natuzzi S.p.A. and EURUSD exchange rate, in particular by considering the relevant time series of the preceding 260 business days.      
Fair value of option at grant date | $       $ 2,458,542  
25% of subscribed capital | €   € 55,073,000 € 54,853,000   € 54,853,000
Amounts owed by related parties | €   € 7,457,000 € 8,028,000   € 7,202,000
American Depository Shares [Member]          
Disclosure of classes of share capital [line items]          
Number of equity-based instruments granted 562,512 562,512      
Number of options, exercised   44,000      
Beneficiary 1 [member]          
Disclosure of classes of share capital [line items]          
Number of equity-based instruments granted 365,334        
Beneficiary 1 [member] | American Depository Shares [Member]          
Disclosure of classes of share capital [line items]          
Fair value of option at grant date | € € 4,390        
Beneficiary 2 [member]          
Disclosure of classes of share capital [line items]          
Number of equity-based instruments granted 65,826        
Beneficiary 2 [member] | American Depository Shares [Member]          
Disclosure of classes of share capital [line items]          
Fair value of option at grant date | € € 4,300        
Beneficiary 3 [member]          
Disclosure of classes of share capital [line items]          
Number of equity-based instruments granted 131,352        
Beneficiary Exercised Option [Member]          
Disclosure of classes of share capital [line items]          
Capital increase | €   € 220,000,000      
25% of subscribed capital | €   55,000,000      
Amounts owed by related parties | €   € 165,000,000      
Beneficiary Exercised Option [Member] | American Depository Shares [Member]          
Disclosure of classes of share capital [line items]          
Number of options, exercised   44,000      
Exercise price of exercised share options | € / shares   € 5.00      
First set vesting through December 31, 2024 [member] | American Depository Shares [Member]          
Disclosure of classes of share capital [line items]          
Number of equity-based instruments granted 110,000        
Second set vesting through December 31, 2027 [member] | American Depository Shares [Member]          
Disclosure of classes of share capital [line items]          
Number of equity-based instruments granted 21,352        
Ordinary shares [member]          
Disclosure of classes of share capital [line items]          
Number of equity-based instruments granted 2,812,560        
Ordinary shares [member] | Beneficiary Exercised Option [Member]          
Disclosure of classes of share capital [line items]          
Number of options, exercised   220,000      
Exercise price of exercised share options | € / shares   € 1.00      
Ordinary shares [member] | First set vesting through December 31, 2024 [member]          
Disclosure of classes of share capital [line items]          
Number of equity-based instruments granted 550,000        
Ordinary shares [member] | Second set vesting through December 31, 2027 [member]          
Disclosure of classes of share capital [line items]          
Number of equity-based instruments granted 106,760